Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agilent To Identify Designer Drugs

by Michael McCoy
March 11, 2013 | A version of this story appeared in Volume 91, Issue 10

[+]Enlarge
Credit: Agilent
Josh Seither, a Ph.D. student at FIU, works with an Agilent LC/MS system.
Photo of Josh Seither, a Ph.D. student at FIU, working with an Agilent LC/MS system.
Credit: Agilent
Josh Seither, a Ph.D. student at FIU, works with an Agilent LC/MS system.

Agilent Technologies is working with Florida International University’s department of chemistry and biochemistry and its International Forensic Research Institute to identify and characterize designer drugs. The partners will develop screening methods based on advanced chromatography and mass spectrometry with the goal of being able to detect about 300 such drugs, which are synthesized to circumvent existing laws. Traditional immunoassay drug-screening methods can’t detect most designer drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.